gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 08 Dec 2016.

Coagulation factor VII

clotting factor
Top mentioned proteins: CAN, HAD, AGE, FVIII, Thromboplastin
Papers on clotting factor
Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
Robinson et al., United States. In Ther Adv Cardiovasc Dis, Feb 2016
Inhibition of clotting factor Xa has been evaluated as a potential target for anticoagulation therapy with the hypothesis that using target-specific therapy will alleviate some of the dosing variability observed with the vitamin K antagonist.
Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.
Carcao et al., Toronto, Canada. In Semin Thromb Hemost, Feb 2016
UNASSIGNED: Management of hemophilia has evolved significantly in the last century-from recognition of the causative mechanism in the 1950s to commercially available clotting factor concentrates in the 1960s.
Hemostatic Efficacy of Pathogen-Inactivated Blood Components.
Ramsey, Chicago, United States. In Semin Thromb Hemost, Jan 2016
UNASSIGNED: Pathogen inactivation (PI), or pathogen reduction technology, reduces the infectious risk of plasma and platelet transfusions, and also affects clotting factor activities and platelet viabilities.
Coagulopathy in liver disease: a balancing act.
Kujovich, Portland, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
The fall in clotting factor levels is accompanied by a parallel fall in anticoagulant proteins.
Acquired bleeding disorders in the elderly.
Kruse-Jarres, Seattle, United States. In Hematology Am Soc Hematol Educ Program, Jan 2016
The hemostatic balance changes with advancing age which may be due to factors such as platelet activation, increase of certain clotting factor proteins, slowing of the fibrinolytic system, and modification of the endothelium and blood flow.
Improving care and treatment options for women and girls with bleeding disorders.
Kulkarni, East Lansing, United States. In Eur J Haematol, Dec 2015
Treatment for HMB should consider patient wishes relating to preservation of fertility, and management options include hormonal measures, desmopressin, antifibrinolytics, platelet concentrate transfusions and clotting factor therapy.
Hemophilic arthropathy of the elbow: prophylaxis, imaging, and the role of invasive management.
Rodríguez-Merchán et al., Houston, United States. In J Shoulder Elbow Surg, Oct 2015
Hemophilia is an X-linked recessive deficiency of clotting factor VIII (hemophilia A) or IX (hemophilia B) that can result in hemarthrosis of various joints, including the elbow.
Emerging and future therapies for hemophilia.
Tortella et al., New Brunswick, United States. In J Blood Med, 2014
In this brief review, the authors summarize data on EHL clotting factors, introduce agents whose mode of action is not clotting factor replacement, and list current gene therapy efforts.
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Schutgens et al., Utrecht, Netherlands. In Cochrane Database Syst Rev, 2014
Secondary objectives were to assess if antifibrinolytic agents can replace or reduce the need for clotting factor concentrate therapy in people with haemophilia or Von Willebrand disease and to further establish the effects of these agents on bleeding in oral or dental procedures for each of these populations.
Is Hydroxyethyl Starch Irrelevant to Hemostasis in Patients Undergoing Liver Transplantation? - In vitro Analysis Based on Thromboelastometry.
Trzebicki et al., Warsaw, Poland. In Ann Transplant, 2014
Fibrinogen, malfunctioning in liver cirrhosis, is the earliest decreasing clotting factor while bleeding.
Association between physical activity and risk of bleeding in children with hemophilia.
Brown et al., Sydney, Australia. In Jama, 2012
The risk of bleeds associated with physical activity was estimated by contrasting exposure to physical activity in the 8 hours before the bleed with exposures in two 8-hour control windows, controlling for levels of clotting factor in the blood.
Modern haemophilia care.
Shapiro et al., Malmö, Sweden. In Lancet, 2012
Early clotting factor concentrates were not sufficiently refined to enable self-administered treatment at home until the 1970s.
Clotting factor gene polymorphisms and colorectal cancer risk.
Brenner et al., Heidelberg, Germany. In J Clin Oncol, 2011
Mainly small studies have addressed the association between clotting factor gene polymorphisms and the onset of colorectal cancer.
Nanoparticles for the delivery of genes and drugs to human hepatocytes.
Kuroda et al., Ibaraki, Japan. In Nat Biotechnol, 2003
When the gene encoding human clotting factor IX was transferred into the xenograft model using L particles, factor IX was produced at levels relevant to the treatment of hemophilia B. The yeast-derived L particle is free of viral genomes, highly specific to human liver cells and able to accommodate drugs as well as genes.
Protein-dependent ribozymes report molecular interactions in real time.
Famulok et al., Bonn, Germany. In Nat Biotechnol, 2002
A simple format switch allowed reliable monitoring of domain-specific interactions between the blood-clotting factor thrombin and its protein partners.
share on facebooktweetadd +1mail to friends